Aldeyra Therapeutics (NASDAQ: ALDX)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-04 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.310 | -0.290 | 0.0200 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Aldeyra Therapeutics (NASDAQ: ALDX) through any online brokerage.
Other companies in Aldeyra Therapeutics’s space includes: Molecular Partners (NASDAQ:MOLN), Outlook Therapeutics (NASDAQ:OTLK), AVEO Pharmaceuticals (NASDAQ:AVEO), Impel Pharmaceuticals (NASDAQ:IMPL) and Innate Pharma (NASDAQ:IPHA).
The latest price target for Aldeyra Therapeutics (NASDAQ: ALDX) was reported by Citigroup on Thursday, June 9, 2022. The analyst firm set a price target for 26.00 expecting ALDX to rise to within 12 months (a possible 584.21% upside). 4 analyst firms have reported ratings in the last year.
The stock price for Aldeyra Therapeutics (NASDAQ: ALDX) is $3.8 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Aldeyra Therapeutics.
Aldeyra Therapeutics’s Q2 earnings are confirmed for Thursday, August 4, 2022.
There is no upcoming split for Aldeyra Therapeutics.
Aldeyra Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.